Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • MS drug candidate shows new promise

  • Pathway that contributes to Alzheimer's disease revealed by research

  • Domestic violence likely more frequent for same-sex couples

  • Physical activity in older adults linked to brain white-matter integrity

  • Targeted radiation, drug therapy combo less toxic for recurrent head, neck cancers

  • 3-D shape processing in brain: New discovery on how objects, places are processed

  • Suicide Prevention Requires Access to Effective, Evidence-Based Treatment

  • Down Syndrome helps researchers understand Alzheimer's disease

  • Providing private mental health service to veterans: Hurdles, challenges, advice

  • Gun deaths twice as high among African-Americans as white citizens in US

  •